Company: LRHC
Filing Date: 2025-07-21
Form Type: DEF 14C
Source: 0001213900-25-065863
Chunk: 19

Company: La Rosa Holdings Corp.
Filing Date: 2025-07-21
Form: DEF 14C
Chunk 19
---
 particular year.

Modification; Amendment; Termination. The Compensation Committee may adopt, establish, amend and rescind such rules, regulations, and procedures as it may
deem appropriate for the proper administration of the Second Amended 2022 Plan, make all other determinations which are, in the Compensation
Committee’s judgment, necessary or desirable for the proper administration of the Second Amended 2022 Plan, amend the Second Amended
2022 Plan or a stock award as provided under the Second Amended 2022 Plan, or terminate or suspend the Second Amended 2022 Plan as provided
therein. The Compensation Committee may also amend the Second Amended 2022 Plan at any time and from time to time. However, except for
adjustments upon changes in common stock, no amendment will be effective unless approved by our stockholders to the extent that stockholder
approval is necessary to preserve incentive stock option treatment for federal income tax purposes. The Compensation Committee may submit
any other amendment to the Second Amended 2022 Plan for stockholder approval if it concludes that stockholder approval is otherwise advisable.

Unless sooner terminated,
the Second Amended 2022 Plan will terminate on January 10, 2023.

The Second Amended 2022 Plan
will be effective no earlier than August 11, 2025, or twenty (20) days after this Information Statement has been made available to our
stockholders, which we expect to be on or approximately July 21, 2025.

<div align='center'>8

EFFECTIVE DATE OF ACTION BY WRITTEN CONSENT</div>

Per Rule 14c-2 under the Exchange
Act, the corporate action taken by written consent becomes effective no earlier than twenty (20) calendar days after the first mailing
or delivery of this Information Statement to stockholders as of the Record Date. This Information Statement provides a comprehensive overview
of the actions approved by the holders of a majority of our outstanding Common Stock.

<div align='center'>DISSENTER’S RIGHTS OF APPRAISAL</div>

Stockholders do not have any
dissenter’s rights or appraisal rights in connection with the approval of the Corporate Actions described in this Information Statement.

<div align='center'>OUTSTANDING VOTING SECURITIES</div>

Each share of Common Stock
grants one vote on each matter submitted to stockholders. Each share of Series X Super Voting Preferred Stock of the Company grants 10,000
Common Stock votes